TY - JOUR
T1 - Copper impairs the intestinal barrier integrity in Wilson disease
AU - Fontes, Adriana
AU - Pierson, Hannah
AU - Bierła, Joanna B.
AU - Eberhagen, Carola
AU - Kinschel, Jennifer
AU - Akdogan, Banu
AU - Rieder, Tamara
AU - Sailer, Judith
AU - Reinold, Quirin
AU - Cielecka-Kuszyk, Joanna
AU - Szymańska, Sylwia
AU - Neff, Frauke
AU - Steiger, Katja
AU - Seelbach, Olga
AU - Zibert, Andree
AU - Schmidt, Hartmut H.
AU - Hauck, Stefanie M.
AU - von Toerne, Christine
AU - Michalke, Bernhard
AU - Semrau, Jeremy D.
AU - DiSpirito, Ana M.
AU - Ramalho-Santos, João
AU - Kroemer, Guido
AU - Polishchuk, Roman
AU - Azul, Anabela Marisa
AU - DiSpirito, Alan
AU - Socha, Piotr
AU - Lutsenko, Svetlana
AU - Zischka, Hans
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/9/1
Y1 - 2024/9/1
N2 - In Wilson disease (WD), liver copper (Cu) excess, caused by mutations in the ATPase Cu transporting beta (ATP7B), has been extensively studied. In contrast, in the gastrointestinal tract, responsible for dietary Cu uptake, ATP7B malfunction is poorly explored. We therefore investigated gut biopsies from WD patients and compared intestines from two rodent WD models and from human ATP7B knock-out intestinal cells to their respective wild-type controls. We observed gastrointestinal (GI) inflammation in patients, rats and mice lacking ATP7B. Mitochondrial alterations and increased intestinal leakage were observed in WD rats, Atp7b−/− mice and human ATP7B KO Caco-2 cells. Proteome analyses of intestinal WD homogenates revealed profound alterations of energy and lipid metabolism. The intestinal damage in WD animals and human ATP7B KO cells did not correlate with absolute Cu elevations, but likely reflects intracellular Cu mislocalization. Importantly, Cu depletion by the high-affinity Cu chelator methanobactin (MB) restored enterocyte mitochondria, epithelial integrity, and resolved gut inflammation in WD rats and human WD enterocytes, plausibly via autophagy-related mechanisms. Thus, we report here before largely unrecognized intestinal damage in WD, occurring early on and comprising metabolic and structural tissue damage, mitochondrial dysfunction, and compromised intestinal barrier integrity and inflammation, that can be resolved by high-affinity Cu chelation treatment.
AB - In Wilson disease (WD), liver copper (Cu) excess, caused by mutations in the ATPase Cu transporting beta (ATP7B), has been extensively studied. In contrast, in the gastrointestinal tract, responsible for dietary Cu uptake, ATP7B malfunction is poorly explored. We therefore investigated gut biopsies from WD patients and compared intestines from two rodent WD models and from human ATP7B knock-out intestinal cells to their respective wild-type controls. We observed gastrointestinal (GI) inflammation in patients, rats and mice lacking ATP7B. Mitochondrial alterations and increased intestinal leakage were observed in WD rats, Atp7b−/− mice and human ATP7B KO Caco-2 cells. Proteome analyses of intestinal WD homogenates revealed profound alterations of energy and lipid metabolism. The intestinal damage in WD animals and human ATP7B KO cells did not correlate with absolute Cu elevations, but likely reflects intracellular Cu mislocalization. Importantly, Cu depletion by the high-affinity Cu chelator methanobactin (MB) restored enterocyte mitochondria, epithelial integrity, and resolved gut inflammation in WD rats and human WD enterocytes, plausibly via autophagy-related mechanisms. Thus, we report here before largely unrecognized intestinal damage in WD, occurring early on and comprising metabolic and structural tissue damage, mitochondrial dysfunction, and compromised intestinal barrier integrity and inflammation, that can be resolved by high-affinity Cu chelation treatment.
KW - Copper
KW - Intestine
KW - Methanobactin
KW - Mitochondria
KW - Wilson disease
UR - http://www.scopus.com/inward/record.url?scp=85198317127&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2024.155973
DO - 10.1016/j.metabol.2024.155973
M3 - Article
AN - SCOPUS:85198317127
SN - 0026-0495
VL - 158
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
M1 - 155973
ER -